MY210310A - Methods for treatment of subjects with psoriatic arthritis - Google Patents
Methods for treatment of subjects with psoriatic arthritisInfo
- Publication number
- MY210310A MY210310A MYPI2021005910A MYPI2021005910A MY210310A MY 210310 A MY210310 A MY 210310A MY PI2021005910 A MYPI2021005910 A MY PI2021005910A MY PI2021005910 A MYPI2021005910 A MY PI2021005910A MY 210310 A MY210310 A MY 210310A
- Authority
- MY
- Malaysia
- Prior art keywords
- treatment
- psoriatic arthritis
- subjects
- methods
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921015050 | 2019-04-15 | ||
| IN202021004422 | 2020-01-31 | ||
| PCT/IB2020/053565 WO2020212874A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY210310A true MY210310A (en) | 2025-09-10 |
Family
ID=72837755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021005910A MY210310A (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220298233A1 (enExample) |
| EP (1) | EP3956357A4 (enExample) |
| JP (2) | JP7628962B2 (enExample) |
| KR (1) | KR20210140780A (enExample) |
| CN (1) | CN113825768A (enExample) |
| AU (1) | AU2020259375A1 (enExample) |
| BR (1) | BR112021020612A2 (enExample) |
| CA (1) | CA3143604A1 (enExample) |
| IL (1) | IL287213A (enExample) |
| JO (1) | JOP20210279A1 (enExample) |
| MA (1) | MA55729A (enExample) |
| MX (1) | MX2021012652A (enExample) |
| MY (1) | MY210310A (enExample) |
| PH (1) | PH12021552536A1 (enExample) |
| SG (1) | SG11202111056YA (enExample) |
| WO (1) | WO2020212874A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202521154A (zh) * | 2023-08-11 | 2025-06-01 | 大陸商信達生物製藥（蘇州）有限公司 | 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗ＩＬ２３ｐ１９抗體治療斑塊狀銀屑病的方法 |
| WO2025051249A1 (zh) * | 2023-09-07 | 2025-03-13 | 信达生物制药(苏州)有限公司 | 一种重组抗IL-23p19抗体治疗中重度银屑病的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| WO2008063213A2 (en) * | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| BRPI0807710B1 (pt) * | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
| WO2010027766A1 (en) * | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| PT2635601T (pt) * | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| WO2014004436A2 (en) * | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
-
2020
- 2020-04-15 WO PCT/IB2020/053565 patent/WO2020212874A1/en not_active Ceased
- 2020-04-15 MA MA055729A patent/MA55729A/fr unknown
- 2020-04-15 AU AU2020259375A patent/AU2020259375A1/en active Pending
- 2020-04-15 BR BR112021020612A patent/BR112021020612A2/pt unknown
- 2020-04-15 JO JOP/2021/0279A patent/JOP20210279A1/ar unknown
- 2020-04-15 SG SG11202111056YA patent/SG11202111056YA/en unknown
- 2020-04-15 JP JP2021561000A patent/JP7628962B2/ja active Active
- 2020-04-15 CA CA3143604A patent/CA3143604A1/en active Pending
- 2020-04-15 PH PH1/2021/552536A patent/PH12021552536A1/en unknown
- 2020-04-15 MY MYPI2021005910A patent/MY210310A/en unknown
- 2020-04-15 KR KR1020217037137A patent/KR20210140780A/ko active Pending
- 2020-04-15 MX MX2021012652A patent/MX2021012652A/es unknown
- 2020-04-15 EP EP20790874.0A patent/EP3956357A4/en active Pending
- 2020-04-15 US US17/603,921 patent/US20220298233A1/en active Pending
- 2020-04-15 CN CN202080029205.6A patent/CN113825768A/zh active Pending
-
2021
- 2021-10-12 IL IL287213A patent/IL287213A/en unknown
-
2025
- 2025-01-30 JP JP2025013906A patent/JP2025069284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021020612A2 (pt) | 2021-12-28 |
| MX2021012652A (es) | 2022-01-24 |
| CN113825768A (zh) | 2021-12-21 |
| KR20210140780A (ko) | 2021-11-23 |
| PH12021552536A1 (en) | 2022-07-04 |
| MA55729A (fr) | 2022-02-23 |
| JP2025069284A (ja) | 2025-04-30 |
| US20220298233A1 (en) | 2022-09-22 |
| JP2022529266A (ja) | 2022-06-20 |
| CA3143604A1 (en) | 2020-10-22 |
| EP3956357A4 (en) | 2023-01-04 |
| EP3956357A1 (en) | 2022-02-23 |
| SG11202111056YA (en) | 2021-11-29 |
| WO2020212874A1 (en) | 2020-10-22 |
| JOP20210279A1 (ar) | 2023-01-30 |
| IL287213A (en) | 2021-12-01 |
| JP7628962B2 (ja) | 2025-02-12 |
| AU2020259375A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| PH12019502755A1 (en) | Antibodies that specifically bind pd-1 and methods of use | |
| MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
| NZ782442A (en) | Antibodies that bind cd39 and uses thereof | |
| MX2025000260A (es) | Proteina de union al antigeno anti-steap1 | |
| MY202336A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| EP4538295A3 (en) | Antigen binding molecules and methods of use thereof | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
| MY187975A (en) | Antigen-binding proteins that activate the leptin receptor | |
| ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
| MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| PH12022551398A1 (en) | Anti-mertk antibodies and methods of use thereof | |
| PH12021552536A1 (en) | Methods for treatment of subjects with psoriatic arthritis | |
| MX2022001947A (es) | Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
| PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2018009696A (es) | Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos. | |
| WO2020003172A8 (en) | Transthyretin antibodies and uses thereof | |
| EA202192416A1 (ru) | Способы лечения субъектов с псориатическим артритом |